Polyclonal SARS-CoV-2 NP antibodies provide an excellent addition to the mix of antibodies to select for COVID-19 Antigen test development.
Our top priority in developing SARS-CoV-2 antibodies is to ensure that our antibodies and tests developed using our antibodies continue to detect the circulating virus variants. While we are confident that assays using a combination of our current monoclonal antibodies detect the main variants, we have now developed polyclonal antibodies specific to the nucleoprotein of SARS-CoV-2 as well. These polyclonal antibodies do not cross-react with seasonal coronaviruses and can be used in combination with our monoclonal anti-NP antibodies.
For test development, we recommend using more than two antibodies as multiple clones decrease the risk of future variants escaping the detection by the test.